Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
This study is currently recruiting patients.
| Sponsored by: | National Cancer Institute (NCI) |
| Information provided: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00575770 |
Purpose:
RATIONALE: Immunotoxins can find tumor cells and kill them without harming normal cells. Drugs used in chemotherapy, such as pemetrexed and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with immunotoxin therapy may kill more malignant mesothelioma cells.
PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.
| Condition | Intervention | Phase |
|
Malignant Mesothelioma |
Biological: SS1(dsFv)-PE38 immunotoxin Drug: cisplatin Drug: pemetrexed disodium Other: immunoenzyme technique Other: immunohistochemistry staining method Other: pharmacological study Procedure: quality-of-life assessment |
Phase 1 |
Eligibility
Study Design: Allocation: Non-Randomized, Control: Active Control, Masking: Open Label, Primary Purpose: Treatment
Official Title: A Phase I, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma
Enrollment Size: Both
Gender: 18 Years
Min. Age: N/A
Max. Age: No
Location and Contact Information
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, 20892-1182, United States
Status: Recruiting
Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937
Last modified: July 29 2010.
